Optimizing Patient Outcomes in High-Risk HR+, HER2- Early-Stage Breast Cancer - Episode 2

NCCN Guidelines vs Real-World Practice: Risk Stratifying HR+/HER2- Early Breast Cancer

Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, examine the NCCN guidelines compared to real-world evidence, particularly in the treatment of menopausal, pre-menopausal, and high-risk early-stage HR+/HER2- patients.

EP. 1: HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification
Now Viewing
EP. 2: NCCN Guidelines vs Real-World Practice: Risk Stratifying HR+/HER2- Early Breast Cancer
EP. 3: 5-Year Data from the MonarchE Trial Investigating Abemaciclib in HR+, HER2- High-Risk, Early Breast Cancer
EP. 4: The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer
EP. 5: AE Management with CDK4/6 Inhibitors: Strategies for Treatment Continuity and Optimal Patient Outcomes
EP. 6: Shared Decision Making and Multidisciplinary Collaboration in the Evolving HR+/HER2- Early-Stage Breast Cancer Landscape

This OncLive Insights video series was supported by an independent sponsorship from Eli Lilly. Eli Lilly had no input into the content or development of this OncLive Insights video series. Content was independently developed and published by OncLive.